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Abstract
Purpose Subependymal giant cell astrocytoma (SEGA) is a
brain tumor associated with tuberous sclerosis complex
(TSC). It usually grows in a second decade of life, but may
develop in the first months of life. The aim of this work was to
establish the incidence, clinical features, and outcome of
congenital SEGA in TSC patients.
Methods Cohort of 452 TSC patients was reviewed to identify
cases with growing or hydrocephalus producing SEGAs in the
first 3 months of life. Clinical presentation, size of the tumor,
growth rate, mutational analysis, treatment applied, and out-
come were analyzed.
Results Ten (2.2 %) patients presented with SEGA in the first
3 months of life. All of them had documented SEGA growth
and all developed hydrocephalus. In eight patients, mutational
analysis was done, and in all of them, TSC2 gene mutations
were identified. Mean maximum SEGA diameter at baseline
was 21.8 mm. Mean SEGA growth rate observed postnatally
was 2.78 mm per month and tended to be higher (5.43 mm per
month) in patients with TSC2/PKD1 mutation than in other
cases. Seven patients underwent SEGA surgery and surgery-
related complications were observed in 57.1 % cases. One
patient was successfully treated with everolimus as a primary
treatment.
Conclusions Congenital SEGA develops 2.2 % of TSC pa-
tients. Patients with TSC2 mutations, and especially with
TSC2/PKD1 mutations, are more prone to develop SEGA
earlier in childhood and should be screened for SEGA from
birth. In young infants with SEGA, both surgery and mTOR
inhibitor should be considered as a treatment option.
Keywords Subependymal giant cell astrocytoma . Tuberous
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Abbreviations
SEGA Subependymal giant cell astrocytoma
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Introduction
Subependymal giant cell astrocytoma (SEGA) is a rare low-
grade brain tumor associated almost exclusively with tuberous
sclerosis complex (TSC) [5, 10, 11]. TSC is a genetically
determined disorder that affects approximately 1 child in
6000 [28]. It is characterized by the development of benign
tumors in various tissues and organs and brain lesions, includ-
ing SEGAs, subependymal nodules (SENs), and cortical tu-
bers as well as epilepsy and its comorbidities, present the
major cause of mortality and morbidity in affected individuals
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[11, 35]. In TSC, inactivatingmutations in either of two genes,
TSC1 or TSC2, lead to hyperactivation ofmammalian target of
rapamycin (mTOR) pathway, which is considered to be a
hallmark of the disease [15, 19]. Mutations in TSC2 were
reported to generate a more severe phenotype than mutations
in TSC1 [6].
Usually, SEGAs grow in children and adolescents, but
there are case reports on neonatal presentation of SEGAs in
TSC patients [1, 13, 22, 24, 25, 27, 31–33, 36]. However,
there are no data on the incidence of SEGAs in newborns and
small infants with TSC and the treatment recommendations
for that age group of patients. Currently, there are two possible
treatment options for SEGA: surgery or mTOR inhibitor,
everolimus, which has been approved for SEGA associated
with TSC by FDA and EMA [3, 14]. The data on safety and
efficacy of any of these treatments in newborns and infants
with SEGA are very limited [7, 18, 20, 25, 32].
The aim of this study was to analyze the incidence, clinical
characteristics, and outcome of inborn SEGA in a large cohort
of TSC patients who were followed at the Children’s Memo-
rial Health Institute, Warsaw.
Material and methods
The study was approved by The Children’s Memorial Health
Institute Ethics Committee. The records of TSC patients, who
had diagnosis of SEGA prenatally or in the first 3 months of
age, were retrospectively reviewed. The inclusion criteria
were as follows: diagnosis of SEGA and clinically definite
TSC based on Roach’s criteria [5]. SEGA was diagnosed
when a tumor was characterized by: location near the foramen
of Monro, diameter ≥1 cm, gadolinium enhancement on neu-
roimaging, and any documented growth, or hydrocephalus
present on baseline neuroimaging. Patients with tumors ex-
ceeding 1 cm in diameter, but not growing or producing
hydrocephalus in the first 3 months of life, were not included
in the study.
The analyzed data included the following: patient demo-
graphics; mutational analysis results; if available, the present-
ing symptoms; size of the tumor; treatment applied; any
adverse events; and results of follow-up neurological exami-
nation and neuroimaging studies.
Results
In a cohort of 452 TSC patients followed at The Children’s
Memorial Health Institute, Warsaw, Poland, 10 (2.2 %) chil-
dren were diagnosed with SEGA in the first 3 months of life.
Five patients (1.1 % of the whole cohort, 50 % of patients
with inborn SEGA) presented with hydrocephalus at baseline,
and in all 10 patients, significant tumor growth was observed
in the first 3 to 6 months of life. There were eight boys and two
girls in this group. Two patients presented clinical symptoms
attributed to brain tumor: early focal seizures (one case) or
hemiparesis (one case). Table 1 presents clinical data of the
patients.
Eight patients had mutational analysis performed and in all
of them, mutation in TSC2 gene was identified. Three of these
mutations (37.5 %) were deletions disrupting not only TSC2
gene but also adjacent PKD1 gene, causing polycystic kidney
disease in these patients.
Mean maximum SEGA diameter at baseline was 21.8 mm.
Figure 1 presents a patient with 13-mm SEGA in the first
week of life. Mean SEGA growth rate observed postnatally
was 2.78 mm per month. Mean SEGA size increased by
5.43 mm per month in patients with TSC2/PKD1 mutations
and by 1.76 and 1.35 mm in patients with other TSC2 muta-
tions and in genetically not tested patients, respectively. The
differences were not statistically significant.
Seven patients underwent SEGA surgery. Five patients had
surgery during infancy (two at the age of 6 weeks, one at the
age of 4 months, one at the age of 8 months, and one at the age
of 18 months). These patients were followed by brain ultra-
sound performed monthly and brain MRI performed every 3–
6 months, and SEGA surgery was done when enlargement of
ventricles was seen. In all of them, shunt was applied either
before (in two patients) or concomitantly (three patients) with
tumor resection.
Two patients had SEGA surgery at the age of 5 and 6 years,
respectively, both presented with acute hydrocephalus at that
time. In both patients, shunt was placed concomitantly with
brain tumor resection. In all operated patients, histopatholog-
ical diagnosis of SEGAwas confirmed.
SEGA was removed totally in six out of seven operated
patients. In all of them, no tumor regrowth was observed
during follow-up of 144.3 months (range 18–180 months).
One patient, in whom SEGAwas removed subtotally, required
several additional surgeries for regrowing tumor and eventu-
ally mTOR inhibitor was introduced with significant
improvement.
Three patients had no surgery. Two of them are still infants
(6 and 4 months of age) and are followed with serial neuro-
imaging studies. In one patient, mTOR inhibitor (everolimus)
was introduced at the age of 12 months. In this case, SEGA
size decreased by 50 % during 4-year follow-up and the
patient is still on treatment.
Surgery-related complications were observed in four pa-
tients (57.1 % of operated cases). Three surgeries were un-
eventful. The complications included the following: persistent
hemiparesis (four patients) and visual impairment (one case).
Five of operated patients developed contralateral SEGA in
18 months to 12 years after the first surgery. Three of them
required second surgery, and two were given medical treat-
ment with everolimus.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Childs Nerv Syst (2014) 30:2037–2042 2039
Altogether, four patients were treated with everolimus:
either as primary treatment (one patient) or because of tumor
regrowth (one case) or because of new SEGA development
(two patients). No new tumor growth was observed in any of
patients treated with everolimus.
Discussion
SEGAs are the most common brain tumors occurring in up to
20 % of the TSC patients, usually in the first two decades of
life [6, 23, 35]. They are typically located on the surface of the
lateral ventricle of the brain, and thus, while growing, they
extend into the lateral ventricle and can obstruct the foramen
of Monro and flow of CSF, causing hydrocephalus [8, 10].
SEGAs usually grow slowly, and the mean age they present
clinical symptoms or cause hydrocephalus is 9.7 years [16, 26,
29, 37]. However, in rare cases, rapid significant increase in
tumor size was observed, especially in the youngest children
[12, 17]. There are also reports on SEGA growth in newborns
and fetuses [13, 31, 33]. Histopathologically, some SEGAs in
very young children may present features of malignancy,
which are not typical for this type of tumor [12].
This is the first analysis of incidence, clinical features, and
outcome of neonatal SEGA in TSC individuals. In our large
cohort of TSC patients, congenital SEGA was present in 10
cases (2.2 %). It is important to note that in this report, inborn
SEGAwas recognized only in patients in whom either hydro-
cephalus associated with SEGA or significant tumor growth
within the first 3 months of age was documented. It cannot be
excluded that some cases of congenital SEGA, which were
asymptomatic at birth and grew slowly, were overlooked in
early infancy and diagnosed later in life. In our group of
patients with early diagnosed SEGA, two had surgery post-
poned to the age of 5 and 6 years, respectively. They required
surgery because of huge tumors and acute hydrocephalus, but
they had been asymptomatic up to this moment. One of those
patients was lost from follow-up for 4 years, and the parents of
the other one did not give consent for surgery as long as the
patient had no SEGA symptoms. Considering those cases, the
possibility that more cases of congenital SEGAs are not being
recognized seems to be likely.
Although rare, congenital SEGAs present significant clin-
ical problem. Surgical treatment of brain tumors in young
infants remains a challenging endeavor, and even in benign
tumors, mortality and morbidity in these patients is higher
than that in other pediatric age groups [21]. In our study, there
were no deaths, but 57 % of operated patients experienced
significant neurological deficits associated with surgery. This
is consistent with our previous reports, showing that age
<3 years is a risk factor for SEGA surgery complications [16].
Five of our operated patients had SEGA resection and
shunt implantations performed during one surgery, and in
two patients, shunt was placed earlier (at the age of 4 and
6 weeks), and SEGA surgery was postponed to the age of 8
and 6 months, respectively. Both approaches were associated
with risk of surgery-related sequelae, although it should be
noted that the patient who had shunt prior to SEGA surgery at
the age of 6 months was the one to have the largest tumor in
the cohort (60 mm in diameter) and SEGA size exceeding
4 cm is an important risk factor for surgery complications [4,
16, 30]. Therefore, it cannot be excluded that in some cases,
earlier shunt implantation and postponed SEGA resection
might be beneficial.
Six out of seven operated patients in this cohort had total
SEGA surgery and in one, partial resection was performed.
Accordingly, to other reports [2, 16, 30], no tumor regrowth
was observed after total SEGA surgery, but several additional
surgeries were performed in a patient after partial resection. It
should be noted, however, that in five patients, contralateral
SEGA developed over the next 1.5 to 12 years. This finding
suggests that patients who had one SEGA might require more
frequent neuroimaging studies than patients who had never
had such tumor.
In our cohort of newborns with SEGA, TSC2 muta-
tions, including TSC2 large deletions affecting PKD1
gene, were identified in all of patients who had muta-
tional analysis done. No patient with inborn SEGA had
TSC1 mutation. It is consistent with our previous studies
showing that SEGA develop significantly more earlier in
individuals with TSC2 mutations than in TSC1 mutation
patients [16]. Moreover, this study shows that patients
with large genomic mutations affecting both TSC2 and
PKD1 genes are at significantly higher risk of early
development of SEGA than patients with other mutations
in TSC2 genes. TSC2/PKD1 mutations account for 2–3 %
Fig. 1 Brain MRI showing SEGA located near the right foramen of
Monro and causing hydrocephalus in a 1-week-old patient with TSC
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of all TSC cases [6, 34], but in our cohort, these mutations
were found in 30 % of patients. Our results indicate that
patients with polycystic kidneys and TSC should be
screened for SEGA from birth.
In this study, SEGAs in patients with PKD1/TSC2 muta-
tions tended to grow more rapidly than in patients with other
TSC2 mutations and patients with unknown mutations. The
differences between the groups were not significant (p=0.19
and 0.21, respectively) but it was likely associated with small
groups. Nevertheless, patients with large PKD1/TSC2 muta-
tions and SEGAs should be followed with frequent neuroim-
aging studies.
Recently, an mTOR inhibitor, everolimus, was ap-
proved by EMA and FDA for medical treatment of
SEGA associated with TSC [9, 14, 18]. The data on
safety of everolimus in infants and young children is
very limited, but in a small cohort of TSC children
below 3 years of age, such treatment was reported to
be safe and effective [17]. In this study, one patient
had everolimus introduced as a primary treatment for
SEGA and one as a adjuvant therapy after partial
SEGA resection, and two additional patients everoli-
mus was started because of the development of contra-
lateral tumor. All these patients are continuing treat-
ment. The patient who is given everolimus for primary
treatment of SEGA at the age of 12 months has been
being followed for 4 years. SEGA size in this child
decreased by 50 %. None of the patients treated with
everolimus developed new tumor, but it should be
noted that in two of them, everolimus was introduced
because of contralateral tumor growth. The possibility
that medical treatment with mTOR inhibitor might pre-
vent or reduce the risk of SEGA development requires
further studies.
In conclusion, we showed that congenital SEGA de-
velops 2.2 % of TSC patients. Patients with TSC2
mutations, and especially with TSC2/PKD1 mutations,
are more prone to develop SEGA earlier in childhood
and should be screened for SEGA from birth. In young
infants with SEGA, both surgery and mTOR inhibitor
should be considered as a treatment option.
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